Home Tags UC-961

Tag: UC-961

Zilovertamab vedotin Demonstrates Encouraging Clinical Activity in B-Cell Cancers

A novel ROR1-targeted antibody-drug conjugate (ADC), zilovertamab vedotin, also known as  MK-2140 or VLS-101, has demonstrated encouraging clinical efficacy, consistent pharmacokinetics, and a favorable...

Oncternal Therapeutics Announces Closing of an $18.4 million Series B Financing.

Clinical-stage biotechnology company Oncternal Therapeutics announced the closing of an $18.4 million Series B financing. The company which develops first-in-class and novel therapies for...